#Ariad Pharmaceuticals (ARIA)

Companies Targeted for Takeover Yet Can Thrive on their Own

It seems that the global Takeda (TKPYY) has guessed well what it should pick in order to bring the most effective targeted treatments to cancer patients allover the globe. Cancer management has unrese...

P

Prohost Biotech

Feb 2, 2017

9m

0

News & Comments

Takeda Acquires Ariad for $5.2 Billion

ARIAD Pharmaceuticals’ (ARIA) stock jumped 75% today. The oncology firm entered into a definitive agreement to be acquired by Takeda Pharmaceutical Company Limited under which Takeda will acquire all...

P

Prohost Biotech

Jan 9, 2017

5m

0

News & Comments

Prohost Take on What's Going on in the Drug Sector

President Elect Trump was quoted in a Time person of the year as saying “I am going to bring down drug prices.” The President Elect did not say he is going to bring down the drug producing and develop...

P

Prohost Biotech

Dec 8, 2016

Prohost Letter #402

Prohost Letter #402 Antisense Proof of Concept and Fea si bility E YE ON INVIVA (INVA) Sales of The Ellipta Inhalers Started to Pick up AND ON THERAVANCE BIOPHARMA (TBPH) See Below AND WE WILL NOT LOS...

P

Prohost Biotech

Nov 30, 2016

Ariad Pharmaceuticals: Substantiating Its Solid Scientific Fundamentals and the Value of Its Strategy

Ariad Pharmaceuticals (ARIA) : Good news from the U.S. Food and Drug Administration (FDA) affirmed that the agency accepted for review Ariad’s New Drug Application (NDA) for its investigational oral a...

P

Prohost Biotech

Nov 1, 2016

Prohost Letter #400

Prohost Letter #400 NEAR-TERM INVESTING Th e Pro h os t L e tt e r # 39 9 Pa r t 3 ha s P ro m i se d t o D es c ri b e t ...

P

Prohost Biotech

Oct 27, 2016

1m

2

News & Comments

Senator Sanders and Ariad

Shares of Ariad Pharmaceuticals declined following Senator Bernie Sanders’ criticism of the high price of the firm’s drug Iclusig (ponatinib) on Twitter. Ariad said, "our pricing reflects our signifi...

P

Prohost Biotech

Oct 17, 2016

Ariad Pharmaceuticals Submits Early NDA for the Approval of Brigatinib. See Also: More News from Ariad

ARIAD Pharmaceuticals (ARIA) announced the initiation of a New Drug Application (NDA) submission for brigatinib , the firm’s investigational anaplastic lymphoma kinase (ALK) inhibitor to the FDA. Earl...

P

Prohost Biotech

Jun 17, 2016

Accelerated FDA Approvals of Immunotherapy Treatments Are Accelerating

CANCER Everyday something new is discovered that explains cancer behavior, including proliferation, response to treatment, resistance to treatment, metastasis, recurrence, etc. Today we have several n...

P

Prohost Biotech

May 19, 2016

Disrupting the Capability of Cancer Cells to Repair Their Damaged DNA. See Also: Underestimated Biotech Firms

Underestimating the Value of Drugs that Disrupt the DNA Repair Mechanisms in Cancer Cells. AstraZeneca’s (AZN) Chief Executive Pascal Soriot said that while DNA damage response was under-recognized by...

P

Prohost Biotech

May 16, 2016

Incyte Acquires Ariad Pharmaceuticals European Operations. See Also: A Great Achievement by Illumina

By June, which is next month, Incyte (INCY) will be the owner of the European operations of Ariad (ARIA) . That’s what both firms have announced yesterday. Among other details, the firms decided on si...

P

Prohost Biotech

May 10, 2016

Prohost Letter #394 Part 2

Prohost Letter #394 Part 2 PART 2 - Part 1 of the Prohost letter issue #394 posted on March 31,2016 ended with the review of Ariad Pharmaceuticals (ARIA), one of the biotech firms that have at least...

P

Prohost Biotech

Apr 4, 2016

Prohost Letter #393

Prohost Letter #393 IMMUNOTHERAPY - PROHOST PORTFOLIO - NEW PICKS? - A Brief Reminder of the CAR T –TCR Immunotherapy Approaches In this issue we continue our journey inside the territory of cancer...

P

Prohost Biotech

Mar 4, 2016

The FDA Delays Reviewing the DMD Drug Kyndrisa. What Happened After Ariad Selected a New CEO?

BioMarin Pharmaceutical (BMRN) announced that the FDA has notified it that they had not yet completed their review process and would be unable to take an action by the Prescription Drug User Fee Act (...

P

Prohost Biotech

Dec 18, 2015

Prohost Letter #384

Prohost Letter #384 The Assassination of the Biotech Sector The Market (Part 2) On Friday September 18, 2015, the biotechnology sector occupied the news headlines for two different reasons. The first...

P

Prohost Biotech

Oct 6, 2015

Prohost Letter #383

Prohost Letter #383 The Market - Recent tails about the market and the biotech sector are true thrillers. By true we mean no-fiction. The accounts lack common sense. Professionals' interpretations of...

P

Prohost Biotech

Sep 25, 2015

Prohost Letter #378 Part 2

Prohost Letter #378 Part 2 2015 ASCO ANNUAL MEETING What a Big Revolution in Oncology! The ASCO meeting projected the huge advancement in the understanding, diagnosing and treating cancer. What looked...

P

Prohost Biotech

Jun 9, 2015

Prohost Letter #378 Part 1

Prohost Letter #378 Part 1 Views and Visions TOP-TIER BIOTECHNOLOGY COMPANIES GILEAD We wrote a lot about Gilead (GILD) , doing our best to protect investors against negative gossip that filled the me...

P

Prohost Biotech

May 27, 2015

Ariad: Harvey Berger is Leaving. What About Now?

WE HEARD ABOUT ARIAD HARVEY BERGER IS LEAVING. WHAT ABOUT NOW? Atiad (ARIA): The head of the firm, Harvey Berger, will retire at the end of the year or when a replacement is found, whichever comes...

P

Prohost Biotech

Apr 30, 2015

Prohost Letter #377

Prohost Letter #377 PICKING BIOTECH FIRMS Before Investing in Them Raising the bar in designating small drug developing firms as biotechnology firms has occurred several times since 2011. In that year...

P

Prohost Biotech

Apr 21, 2015

1m

0